Filing Flows › Companies › Neurocrine Biosciences › Timeline
Neurocrine Biosciences stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+6.3% to $164.63
Neurocrine Biosciences (NBIX) stock rose 6% over the last 252 sessions, to $164.63. On the way it reported 4 quarters, its insiders filed no open-market trades (10b5-1 plan sales aside) and 10 Form 144 notices of planned sales, and the company filed 5 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 2, 2026 | Earnings | Earnings: beat the EPS estimate by 19.8% | −0.5% (0.0% vs SPY) | +11.9% (+14.7% vs SPY) | — |
| Nov 2, 2026 | Form 144 | Form 144: George Morrow plans to sell $2.1M | −0.5% (0.0% vs SPY) | +11.9% (+14.7% vs SPY) | — |
| Oct 30, 2026 | Form 144 | Form 144: George Morrow plans to sell $44K | −0.2% (+1.6% vs SPY) | +8.8% (+13.6% vs SPY) | — |
| Sep 28, 2026 | 8-K | Directors and officers: departures, appointments, pay | −1.5% (−1.3% vs SPY) | +2.6% (+1.4% vs SPY) | +3.9% (+3.4% vs SPY) |
| Sep 14, 2026 | Form 144 | Form 144: David Warren Boyer plans to sell $736K | +0.6% (+1.1% vs SPY) | −6.6% (−6.5% vs SPY) | −10.0% (−12.0% vs SPY) |
| Sep 14, 2026 | Form 144 | Form 144: Matthew C Abernethy plans to sell $361K | +0.6% (+1.1% vs SPY) | −6.6% (−6.5% vs SPY) | −10.0% (−12.0% vs SPY) |
| Sep 9, 2026 | Form 144 | Form 144: Eric Benevich plans to sell $334K | 0.0% (+0.5% vs SPY) | −3.3% (−2.2% vs SPY) | −7.8% (−9.5% vs SPY) |
| Jul 30, 2026 | Earnings | Earnings: beat the EPS estimate by 45.4% | +2.6% (+0.9% vs SPY) | −11.3% (−16.7% vs SPY) | −14.8% (−20.4% vs SPY) |
| Jul 10, 2026 | Form 144 | Form 144: Ingrid Delaet plans to sell $788K | −1.9% (−2.4% vs SPY) | −5.1% (−5.0% vs SPY) | −10.0% (−12.8% vs SPY) |
| Jul 9, 2026 | Form 144 | Form 144: Darin Lippoldt plans to sell $1.8M | +1.3% (+0.5% vs SPY) | −3.5% (−4.8% vs SPY) | −10.9% (−14.0% vs SPY) |
| Jul 7, 2026 | Form 144 | Form 144: Ingrid Delaet plans to sell $2.5M | +1.9% (+2.4% vs SPY) | 0.0% (+0.3% vs SPY) | −4.7% (−7.4% vs SPY) |
| Jun 29, 2026 | Form 144 | Form 144: Darin Lippoldt plans to sell $1.7M | +0.9% (−0.8% vs SPY) | +3.3% (+0.2% vs SPY) | +8.2% (+6.5% vs SPY) |
| Jun 26, 2026 | Form 144 | Form 144: Darin Lippoldt plans to sell $33K | +2.6% (+3.3% vs SPY) | +6.0% (+4.5% vs SPY) | +7.2% (+6.6% vs SPY) |
| May 28, 2026 | 8-K | Directors and officers: departures, appointments, pay | +1.2% (+1.0% vs SPY) | +6.8% (+6.4% vs SPY) | +8.3% (+9.9% vs SPY) |
| May 18, 2026 | 8-K | Material definitive agreement | −0.8% (−0.7% vs SPY) | −1.1% (−2.0% vs SPY) | −1.3% (−2.8% vs SPY) |
| May 5, 2026 | Earnings | Earnings: beat the EPS estimate by 14.4% | +0.7% (−0.1% vs SPY) | +11.6% (+8.7% vs SPY) | +20.8% (+15.9% vs SPY) |
| Apr 6, 2026 | 8-K | Material definitive agreement | +0.7% (+0.2% vs SPY) | −2.1% (−5.6% vs SPY) | +1.8% (−7.2% vs SPY) |
| Feb 11, 2026 | Earnings | Earnings: missed the EPS estimate by -18.1% | −0.2% (−0.1% vs SPY) | −7.0% (−6.1% vs SPY) | −7.4% (−3.6% vs SPY) |
| Nov 24, 2025 | 8-K | Directors and officers: departures, appointments, pay | +1.6% (+0.7% vs SPY) | +7.7% (+5.8% vs SPY) | +3.9% (+0.5% vs SPY) |
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
| 1.01 Material definitive agreement | 23,525 | 0.0% | 51% | +1.0% | ±1.4% |
| 2.01 Completed acquisition or disposition | 2,671 | +0.1% | 52% | +1.2% | ±1.6% |
| 2.03 New debt or off-balance-sheet obligation | 13,268 | 0.0% | 50% | +1.2% | ±1.3% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Neurocrine Biosciences: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.